The report provides a snapshot of the global therapeutic landscape of Cancer Cachexia
The high incidence and mortality rates of cancer cachexia
attract much attention in recent years (Morley et al.
PsiOxus), a development stage biotechnology company, has completed patient enrollment for its Phase II clinical trial to study MT-102, a small molecule therapeutic for the treatment of cancer cachexia
Many strong studies now demonstrate that the carnitine supplements can reduce the rate and severity of cancer cachexia
Kumar and colleagues suggest that eicosapentaenoic acid (EPA) might be helpful in preventing and treating cancer cachexia
impairs quality of life and response to therapy, increasing morbidity and mortality of cancer patients.
The current scientific consensus is that cancer cachexia
results primarily from an underlying metabolic imbalance induced by the cancer, causing the body's metabolism to speed up," explains Keith Block, medical director of the Block Center for Integrative Cancer Care, Evanston, Ill.
The Cancer Cachexia
guidelines were developed by an expert group of Australian dietitians experienced in the area (Cancer Cachexia
is commonly associated with advanced or late-stage cancer.
Specific cancer studies include: multiple myeloma, leukemia, glioblastoma, renal cancer, cancer cachexia
and colorectal cancer.
Objective: Cancer cachexia
is a life-threatening syndrome characterized by severe body weight loss, due to depletion of adipose tissue and skeletal muscle, and affects up to 80% of patients with advanced cancers.
Thus, the management of cancer cachexia
is primordial to achieve a successful treatment.
Kumar and Hindi believe their research ultimately will lead to improved treatments for muscle wasting diseases such as muscular dystrophy, ALS, cancer cachexia
, diabetes, heart disease and others.
- Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
MT-102 is the most advanced product and is in mid-stage clinical trials for the treatment of cancer cachexia
and the company's second product, ColoAd1, is an oncolytic virus that is scheduled to enter clinical trials in 2012.